DeCure for Allergic bronchopulmonary aspergillosis
DeCure's autonomous Respiratory AI scientist is researching a drug-repurposing hypothesis for allergic bronchopulmonary aspergillosis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAllergic bronchopulmonary aspergillosis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for allergic bronchopulmonary aspergillosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 1 (NR3C1) — NR3C1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7KW7 · 3.57 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Since 1968 the number of reported cases of allergic bronchopulmonary aspergillosis in the United States has risen, attributed to increased physician awareness and improved diagnostic criteria. The disease is caused by hypersensitivity to colonised Aspergillus fumigatus, mostly affecting susceptible adults with asthma or cystic fibrosis. Eight diagnostic criteria, five clinical stages, common radiographic changes, pathologic findings, laboratory findings, possible pathogenetic mechanisms, differential diagnosis, and acute and chronic pulmonary function changes have been described. Corticosteroid therapy is considered important for treating exacerbations and preventing further lung damage.
A 2018 case report describes a 10-year-old asthmatic girl with ABPA who was treated with low dose corticosteroids combined with itraconazole for three months. The authors report that this regimen successfully reduced clinical symptoms, decreased lung infiltrates, and stopped progression to chronic lung disease. They suggest that in financial constraint circumstances, ABPA in children can be successfully treated without anti-IgE therapy. However, this is a single case, and the authors note that treatment strategies used in ABPA children are limited in the literature.
A 2012 review summarised studies on ABPA published between December 2006 and December 2011, but the abstract provides no specific numerical results, response rates, or survival data. The 1983 review similarly offers no quantitative outcomes from controlled trials. No drug other than corticosteroids and itraconazole is mentioned in any of these abstracts.
What is still missing are large, controlled trials in children and adults that report objective response rates, lung function changes, and long-term outcomes. The evidence base for itraconazole in children rests on a single case. No randomised comparisons of corticosteroid-sparing regimens or anti-IgE therapy versus standard care are provided. Patient stratification by disease stage or underlying condition (asthma versus cystic fibrosis) has not been tested in prospective studies. Funding for such trials, rather than further case reports or narrative reviews, is needed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Internal Medicine · 1983 · 40 citations
Allergic Bronchopulmonary Aspergillosis
Abstract• Since 1968 the number of reported cases of allergic bronchopulmonary aspergillosis in the United States has risen secondary to increased awareness by physicians and to improved diagnostic criteria for identifying the disease. The eight diagnostic criteria, the five clinical stages of the disease, the common radiographic changes, the pathologic findings, the common laboratory findings, the possible pathogenetic mechanisms involved, the differential diagnosis, the acute and chronic pulmonary function changes, and the importance of corticosteroid therapy in treatment of exacerbations and prevention of further lung damage are reviewed. (<i>Arch Intern Med</i>1983;143:1553-1557)
Therapeutic Advances in Respiratory Disease · 2012 · 39 citations · open access
Management of allergic bronchopulmonary aspergillosis: a review and update
AbstractSince the first description of allergic bronchopulmonary aspergillosis (ABPA) in the 1950s there have been numerous studies that have shed light on the characteristics and immunopathogenesis of this disease. The increased knowledge and awareness have resulted in earlier diagnosis and treatment of patients with this condition. This article aims to provide a summary and updates on ABPA by reviewing the results of recent studies on this disease with a focus on articles published within the last 5 years. A systematic search of PubMed/Medline with keywords of ABPA or allergic bronchopulmonary aspergillosis was performed. All selected articles were reviewed with a focus on findings of articles published from December 2006 to December 2011. The relevant findings are summarized in this paper.
Archives of Internal Medicine · 1983 · 8 citations
Allergic bronchopulmonary aspergillosis
Abstract• Since 1968 the number of reported cases of allergic bronchopulmonary aspergillosis in the United States has risen secondary to increased awareness by physicians and to improved diagnostic criteria for identifying the disease. The eight diagnostic criteria, the five clinical stages of the disease, the common radiographic changes, the pathologic findings, the common laboratory findings, the possible pathogenetic mechanisms involved, the differential diagnosis, the acute and chronic pulmonary function changes, and the importance of corticosteroid therapy in treatment of exacerbations and prevention of further lung damage are reviewed. (<i>Arch Intern Med</i>1983;143:1553-1557)
Internal Medicine · 2021 · 3 citations · open access
Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan
AbstractA 16-year-old boy with asthma participated in recovery volunteer work following the 2018 heavy rains in Japan. One month later, he experienced chest pain and dyspnea. Chest computed tomography revealed a cavity with a fungal ball, and Aspergillus fumigatus was detected in his bronchoalveolar lavage fluid. He was treated with voriconazole, but new consolidations appeared rapidly. He also experienced allergic bronchopulmonary aspergillosis. After prednisolone prescription, the consolidations improved; however, his asthma worsened. He underwent partial lung resection to avoid allergens, and his symptoms improved. We must recognize cases of infection after a disaster, especially in patients with chronic respiratory diseases.
The Professional Medical Journal · 2018 · 0 citations · open access
ASPERGILLOSIS
AbstractAllergic bronchopulmonary aspergillosis (ABPA) is an illness caused byhypersensitivity to colonized Aspergillus fumigatus, mostly involving susceptible adult patientswith history of asthma and cystic fibrosis. Timely given appropriate treatment can reduceclinical symptoms, decrease lung infiltrates and stop progression to chronic lung disease. Inliterature review, treatment strategies used in ABPA children are limited. Herein we present acase of 10-year old asthmatic girl who, on developing ABPA, was successfully treated by theuse of low dose corticosteroids combined with itraconazole for 3 months duration. We suggestthat in financial constraint circumstances, ABPA in children can be successfully treated withoutanti-IgE therapy.
The Professional Medical Journal · 2018 · 0 citations · open access
ASPERGILLOSIS
AbstractAllergic bronchopulmonary aspergillosis (ABPA) is an illness caused byhypersensitivity to colonized Aspergillus fumigatus, mostly involving susceptible adult patientswith history of asthma and cystic fibrosis. Timely given appropriate treatment can reduceclinical symptoms, decrease lung infiltrates and stop progression to chronic lung disease. Inliterature review, treatment strategies used in ABPA children are limited. Herein we present acase of 10-year old asthmatic girl who, on developing ABPA, was successfully treated by theuse of low dose corticosteroids combined with itraconazole for 3 months duration. We suggestthat in financial constraint circumstances, ABPA in children can be successfully treated withoutanti-IgE therapy.
Treatment of allergic bronchial pulmonary aspergillosis
AbstractAllergic bronchial pulmonary aspergillosis is a kind of lung disease that is a body of the parasitic in the bronchial aspergillus caused by allergic reactions.This disease usually occurs in patients with asthma and cystic fibrosis.Due to China′s high incidence of asthma, to improve the awareness of asthma in patients with allergic broncho-pulmonary aspergillosis and timely treatment are particularly important.Glucocorticoid inhibition of immune inflammatory response combined with antifungal agents to reduce fungal load is the main treatment.There are also anti-IgE treatment and other treatment.
Key words:
Bronchial pulmonary aspergillosis; Asthma; Treatment
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
